C4 Therapeutics Q1 2026 Earnings Strong EPS Beat Highlights Cost Discipline Amid PreRevenue Stage Everest Group EG Q1 2026 Earnings Strong EPS Beat Amid Stable Underwriting Conditions AFLAC Q1 2026 Earnings EPS Miss Estimates Amid Stable Operations Safe Bulkers Q4 2025 Earnings EPS Misses Estimates Shares Edge Lower AVAL Q2 2025 Earnings Strong EPS Performance Despite Market Headwinds Traws Pharma Q1 2026 Earnings Narrower Than Expected Loss Despite No Revenue